¿QUE ES EL ASMA? definición, FISIOPATOLOGIA, DIAGNOSTICO Y ABORDAJE 2022 ACTUALIZADO #asma GINA 💊

Introduction to Asthma

In this section, the speaker introduces the topic of asthma and discusses the guidelines from GINA (Global Initiative for Asthma) and GEMA (Guía Española para el Manejo del Asma). The definition, risk factors, pathophysiology, clinical manifestations, diagnosis, and management of asthma will be covered.

Definition of Asthma

• Asthma is defined as a heterogeneous disease characterized by chronic inflammation of the airways.

• Symptoms include wheezing, dyspnea, chest tightness, and variable airflow limitation.

Pathophysiology of Asthma

• Asthma is caused by chronic inflammation of the airways due to exposure to antigens such as pollen.

• Antigens are captured by dendritic cells and presented to T-helper lymphocytes.

• Th2 lymphocytes release cytokines that activate plasma cells to produce IgE.

• IgE sensitizes mast cells for degranulation upon re-exposure to antigens, leading to bronchoconstriction, mucosal edema, and mucus hyperproduction.

Clinical Manifestations of Asthma

• Cardinal symptoms include expiratory wheezing, coughing, dyspnea, and chest tightness.

• Symptoms vary in time and intensity and can be triggered by exercise or allergen exposure.

Risk Factors for Asthma

• Host factors: atopy (allergic tendency) and rhinitis.

• Perinatal factors: preeclampsia and prematurity.

• Environmental factors: tobacco smoke exposure and allergen exposure.

Diagnosis of Asthma

This section focuses on diagnosing asthma based on clinical suspicion and spirometry tests. Key questions to ask patients suspected of having asthma are also discussed.

Clinical Suspicion of Asthma

• Diagnosis is based on clinical suspicion, considering cardinal symptoms such as dyspnea, chest tightness, wheezing, and coughing.

• Additional questions to ask patients include a history of nighttime symptoms, exposure to triggers (animals, plants, tobacco), and use of rescue medication.

Spirometry Test

• Spirometry is a lung function test that measures volumes and capacities of the lungs.

• It evaluates tidal volume, inspiratory reserve volume, expiratory reserve volume, and more.

• Pre- and post-bronchodilator spirometry can help assess airflow limitation.

Conclusion

The speaker concludes by summarizing the importance of understanding asthma's definition, pathophysiology, clinical manifestations, risk factors, and diagnostic approach. Spirometry plays a crucial role in confirming the diagnosis.

Respiratory System Overview

This section provides an overview of the respiratory system and its various components.

Key Points:

• The forced expiratory volume in one second (FEV1) measures the volume of air forcefully exhaled in one second.

• The residual volume is the amount of air that remains in the alveoli after expiration.

• Capacities are sums of volumes, such as inspiratory capacity (tidal volume + inspiratory reserve volume).

Spirometry and Asthma Diagnosis

This section discusses spirometry and how it can be used to diagnose asthma.

Key Points:

• In spirometry, a pattern of obstructive lung disease is observed in patients with asthma, indicated by a FEV1/FVC ratio less than 0.7 or 70%.

• Bronchodilator response testing can be performed to determine if a patient with suspected asthma responds positively to bronchodilators.

• If the FEV1 improves by at least 12% and 200 mL after bronchodilator administration, it indicates a positive response and confirms the diagnosis of asthma.

Diagnostic Algorithm for Asthma

This section presents a diagnostic algorithm for asthma based on clinical suspicion and additional tests.

Key Points:

• The diagnostic algorithm involves performing pre-and post-bronchodilator spirometry to assess for obstructive patterns (FEV1/FVC < 0.7).

• If there is a positive bronchodilator response (FEV1 improvement ≥12% and 200 mL), the patient is diagnosed with asthma.

• Other tests like nitric oxide measurement or bronchoconstrictor challenge can be used if the diagnosis is uncertain.

• Peak flow variability of more than 10% can also indicate asthma.

Components of Asthma Management

This section discusses the different components involved in managing asthma.

Key Points:

• The first component is determining the control of asthma, which involves assessing symptoms and using scoring systems like GINA to classify control levels.

• The second component includes pharmacological and non-pharmacological management strategies.

• Non-pharmacological management may involve smoking cessation, individualized care based on comorbidities, and addressing risk factors.

• Pharmacological management follows a stepwise approach, with inhaled corticosteroids (ICS) being the mainstay treatment. The SMART therapy approach is commonly used.

Determining Asthma Control

This section explains how to determine the level of asthma control using scoring systems.

Key Points:

• The GINA scoring system assesses asthma control based on symptoms. Patients are categorized as well-controlled, partially controlled, or uncontrolled based on specific criteria.

• Other scoring systems like ACT and ACQ can also be used to evaluate asthma control.

Pharmacological and Non-pharmacological Management

This section discusses both pharmacological and non-pharmacological approaches to managing asthma.

Key Points:

• Non-pharmacological management includes smoking cessation, individualized care for comorbidities, weight management for obesity, and addressing gastroesophageal reflux disease (GERD).

• Exercise should not be avoided unless specifically advised by a healthcare professional.

• Pharmacological management follows a stepwise approach using inhaled corticosteroids (ICS) combined with formoterol. Different steps are determined based on symptom frequency and lung function.

Stepwise Approach to Pharmacological Management

This section explains the stepwise approach to pharmacological management of asthma.

Key Points:

• The stepwise approach consists of five steps, with each step involving different doses of inhaled corticosteroids (ICS) combined with formoterol.

• Step 1 and 2 are for patients with fewer symptoms, while Step 3, 4, and 5 are for patients with more frequent or severe symptoms.

• Higher steps may require referral to a specialist for further management options like high-dose ICS or monoclonal antibodies targeting interleukin-5.

New Section

In this section, the speaker discusses the different steps of asthma treatment based on the severity of symptoms and frequency of occurrence. The speaker also mentions the importance of patient education and adherence to inhaler usage.

Steps of Asthma Treatment

• Step 3: This step is for patients who experience asthma symptoms almost every day and wake up due to asthma. They are prescribed low-dose medications.

• Step 4: Patients in this step have daily symptoms and a decrease in lung function. They require higher doses of medication.

• Step 5: Patients at this stage are referred to a pulmonologist or internist for further treatment.

Follow-up and Medication Adjustment

• After initiating treatment, follow-up visits occur every 1 to 3 months.

• Once the patient's condition stabilizes, follow-up visits are scheduled every 3 months to a year.

• Based on the patient's response, medication may be escalated or deescalated. For example, if a patient responds well at Step 2, they may be considered for deescalation to Step 1.

Importance of Education and Adherence

• Patient education plays a crucial role in ensuring proper inhaler usage.

• It is important for patients to understand how to correctly use their inhalers.

• Assessing adherence through tools like inhaler adherence tests can help monitor patient compliance.

New Section

In this section, the speaker discusses the frequency of follow-up visits after initiating treatment and stabilizing the patient's condition. The decision to escalate or deescalate medication is also mentioned.

Follow-up Visits

• After starting treatment, follow-up visits occur every 1 to 3 months.

• Once the patient's condition stabilizes, follow-up visits are scheduled every 3 months to a year.

Medication Adjustment

• Based on the patient's response to treatment, medication may be escalated or deescalated.

• If a patient responds well at Step 2, consideration may be given to deescalating to Step 1.

• Conversely, if a patient does not respond well, medication may be escalated, such as moving from Step 2 to Step 3.

New Section

In this section, the speaker emphasizes the importance of patient education and adherence in asthma management. The use of inhaler adherence tests is mentioned as a tool for assessing patient compliance.

Importance of Education and Adherence

• Proper education on inhaler usage is crucial for patients.

• Ensuring patients are using their inhalers correctly is extremely important.